Health Canada Product Monograph
While health canada reviews the product monograph or the veterinary labelling as.
Health canada product monograph. In 2016 health canada announced the goal of adopting a structured format for drug product information. The dpd is updated nightly and includes. A product monograph is intended to provide the necessary information for the safe and effective use of a new drug and also to serve as a standard against which all promotion and advertising of the drug can be compared.
Product monograph pm for human drugs. The veterinary labelling is developed by the drug sponsor according to the food and drug regulations. Search the drug product database dpd to find drugs authorized for sale by health canada.
Health canada s commitment to make product monographs available in both official languages is in line with the official language act and with the department s goals for increased openness and transparency. Structured formats for drug information is not new. Spl is used by the fda community to facilitate drug listings establishment registration ndc labeler code requests and registrations and other fda required reporting.
Compendium of monographs guidance document this document outlines and describes what a monograph is and how it can be used in a product application for natural health products sold in canada. It also responds to demands from stakeholders including the public for greater access to health canada authorized drug product information. The database provides information on acceptable medicinal and non medicinal ingredients standard terminology and single ingredient and product monographs.
In the united states the fda requires spl structured product labeling which is a document markup standard in xml format. B new address for canada vigilance program 2010 02 17. Health canada workshop on health product plain language labelling 2011 07 21 notice product monograph template revisions.
Availability of the drug in canada. Health canada reviews the product monograph as part of the drug review process as it forms an integral part of a new drug submission. A new boxed message insert for overdose management information.